Recent News for ENLV - Enlivex Therapeutics Ltd.

Date Title
Mar 29 Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis Market
Mar 22 Enlivex enters Allocetra research collaboration with Yale Cancer Center
Mar 22 Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors
Mar 9 Enlivex Announces Upcoming Virtual Investor Conference Participations
Mar 8 Enlivex gets notice of allowance for Allocetra Japanese patent application
Mar 8 Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies
Mar 1 Enlivex and Mount Sinai to explore potential of Allocetra with checkpoint inhibitors
Mar 1 Enlivex and Mount Sinai Health System announce research collaboration deal
Mar 1 Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
Feb 22 Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
Feb 18 Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
Feb 16 Enlivex nabs new U.S. patent for Allocetra, shares up 6%
Feb 16 Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
Feb 12 Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
Feb 10 Enlivex Therapeutics shares down 9% on capital raise via equity offering
Feb 10 Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
Feb 9 Enlivex Therapeutics slumps 10% on $10M capital raise
Feb 9 Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
Feb 9 TLRY, GLUU, ABEO and TYME among premarket gainers
Feb 9 The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Feb 9 105 Biggest Movers From Yesterday
Feb 3 Enlivex Rallies On Encouraging Allocetra Data In Mid-Stage COVID-19 Study
Feb 3 Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 3 Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
Jan 11 Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Back to the Main ENLV Page...